• Ismael Francisco Aomar-Millán, Juan Salvatierra, Úrsula Torres-Parejo, María Nuñez-Nuñez, José Hernández-Quero, and Francisco Anguita-Santos.
• Servicio de Medicina Interna, Hospital Universitario San Cecilio, Granada, España. Electronic address: iaomarmillan@hotmail.com.
• Med Clin (Barc). 2021 Jun 25; 156 (12): 602605602-605.

AimTo assess clinical outcomes according to the immunosuppressive treatment administered to patients with severe SARS-CoV-2 pneumonia and moderate inflammation.MethodsA retrospective observational cohort study involving 142 patients with severe COVID-19 pneumonia and moderate inflammation divided into three treatment groups (pulses of methylprednisolone alone [groupI], tocilizumab alone [groupII] and methylprednisolone plus tocilizumab [groupIII]). The aim was to assess intergroups differences in the clinical course with a 60-day follow-up and related analytical factors.Results14 patients (9,8%) died: 8 (10%) in groupI and 6 (9,5%) in groupsII andIII. 15 (10,6%) were admitted to ICU: 2 (2,5%) from groupI, 4 (28,5%) from groupII and 9 (18,4%) from groupIII. The mean hospital stay was longer in groupII and clinical outcome was not associated with treatment.ConclusionsTocilizumab seems to be not associated with better clinical outcomes and should be reserved for clinical trial scenario, since its widespread use may result in higher rate of ICU admission and longer mean hospital stay without differences in mortality rate and potentially adverse events.Copyright © 2021 Elsevier España, S.L.U. All rights reserved.

18 keywords...

hide…